ASTEX PHARMACEUTICALS, INC Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2012-12-12: Form 8-K; Period of report 2012-12-06; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2012-10-30: Form 8-K; Period of report 2012-10-30; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2012-09-28: Form 8-K; Period of report 2012-09-28; Description 8.01 Other Events; Details 8.01.
- 2012-09-24: Form 8-K; Period of report 2012-09-21; Description 8.01 Other Events; Details 8.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2012-12-12 | 8-K | 2012-12-06 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On December 6, 2012, the Astex Pharmaceuticals Compensation Committee approved cash bonus awards to the executive officers of the company for their performance in calendar year 2012. | a12-28882_18k.htm |
| 2012-10-30 | 8-K | 2012-10-30 | 2.02 Results of Operations and Financial Condition | 2.02 On October 30, 2012, Astex Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and nine months ended September 30, 2012. | a12-25556_18k.htm |
| 2012-09-28 | 8-K | 2012-09-28 | 8.01 Other Events | 8.01 On September 28, 2012, Astex Pharmaceuticals, Inc. issued a press release announcing that the European Commission has approved the marketing authorization for Dacogen® (decitabine) for Injection for the treatment of adult patients (age 65 and above) with newly diagnosed de novo or secondary acute myeloid leukemia (AML), according to the World Health Organization classification, who are not candidates for standard induction chemotherapy. | a12-22331_18k.htm |
| 2012-09-24 | 8-K | 2012-09-21 | 8.01 Other Events | 8.01 On September 21, 2012, Astex Pharmaceuticals, Inc. issued a press release announcing that clinical development of amuvatinib (MP-470), a multi-targeted tyrosine kinase inhibitor, has been discontinued. | a12-21926_18k.htm |
| 2012-07-30 | 8-K | 2012-07-30 | 2.02 Results of Operations and Financial Condition | 2.02 On July 30, 2012, Astex Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and six months ended June 30, 2012. | a12-17231_18k.htm |
| 2012-06-28 | 8-K | 2012-06-22 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 (e) (1) On June 22, 2012, the Compensation Committee of the Board approved an amended and restated Contract of Employment between Astex Therapeutics Limited and Dr. Harren Jhoti, and an amended and restated Confidentiality and Proprietary Information Deed between Astex Pharmaceuticals, Inc., Astex Therapeutics Limited (a wholly owned subsidiary of Astex Pharmaceuticals, Inc.) and Dr. Jhoti. | a12-15584_18k.htm |
| 2012-06-25 | 8-K | 2012-06-22 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 The Annual Meeting of Stockholders of Astex Pharmaceuticals, Inc., a Delaware corporation (the “Company”) was held on June 22, 2012. | a12-15314_18k.htm |
| 2012-04-30 | 8-K | 2012-04-30 | 2.02 Results of Operations and Financial Condition | 2.02 On April 30, 2012, Astex Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2012. | a12-10805_18k.htm |
| 2012-03-13 | 8-K | 2012-03-07 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On March 7, 2012, the Astex Pharmaceuticals Compensation Committee approved cash bonus awards to certain of the executive officers of the company for their performance in calendar year 2011. | a12-6986_18k.htm |
| 2012-03-05 | 8-K | 2012-03-05 | 2.02 Results of Operations and Financial Condition | 2.02 On March 5, 2012, Astex Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2011. | a12-6428_18k.htm |
| 2012-01-20 | 8-K | 2012-01-13 | 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement | 1.01 On January 13, 2012, the Company entered into an Asset Transfer Agreement with GlaxoSmithKline LLC, a Delaware limited liability company (“GSK”). 1.02 As described in 1.01 above, the Asset Transfer Agreement effectively terminates the Original Agreement, which GSK and the Company entered into on November 9, 2009. | a12-3165_18k.htm |